We are proud to share that Orei Health has been selected as one of the finalists of the CatapultX Health Venture Debt Accelerator 2024, organised by CatapultX Accelerator in partnership with EIT Health InnoStars.
The programme attracts some of the most innovative health and medtech startups with the potential to deliver breakthrough solutions that transform healthcare. This year’s edition saw outstanding interest from startups across countries participating in the EIT Regional Innovation Scheme (EIT RIS), reflecting the growing strength of the health innovation ecosystem in the region.
A highly competitive field
The finalists were chosen for the quality of their technological solutions, well-developed growth strategies, and strong potential to scale and commercialise internationally.
The finalists of the CatapultX Health Venture Debt Accelerator 2024 are:
-
Sentum (Spain)
-
Aequilibrium Pharma (Italy)
-
Alpha Powders (Poland)
-
ABAStroke (Poland)
-
Aura System Srl (Italy)
-
Biovalley – BIONwoven (Poland)
-
Orei Health (Poland)
-
BrainScan SA (Poland)
-
EFM SA (Poland)
-
Insimili (Italy)
Why this matters for Orei Health
Our selection as a finalist highlights the innovation and market potential behind Orei One – our painless, stress-free, at-home blood collection device.
It’s another step forward in our mission to remove global barriers to preventive healthcare and diagnostics, and an opportunity to connect with investors, mentors, and partners who share our vision of patient-centred innovation.
Acknowledgements
We would like to thank the programme organisers and partners for this recognition, as well as for their support in empowering health startups to scale:
Santander Bank Polska, BNP Paribas, i&i Biotech Fund, Google for Startups, Nicolas Beuzen, Angéla Gusztos, Tamás Békási, Viktor Todorov, MBA, F6S, Santander X.
